Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957957 | 0.80 | MEN1 (0.43) | MEN1KMT2AMCL1 | |
| SCHEMBL18894226 | 0.76 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL7701818 | 0.75 | MEN1 (0.54) | MEN1KMT2A | |
| SCHEMBL5072444 | 0.73 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL16013551 | 0.71 | MGLL (0.35) | MGLL | |
| SCHEMBL5556294 | 0.71 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL18920267 | 0.71 | MEN1 (0.56) | MEN1KMT2A | |
| SCHEMBL10035881 | 0.70 | MEN1 (0.46) | MEN1KMT2A | |
| SCHEMBL14566372 | 0.68 | MEN1 (0.55) | MEN1KMT2A | |
| SCHEMBL723300 | 0.68 | KMT2A (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11027027-B2 | Pyridazinoindole compounds and methods for PET imaging | VANDERBILT UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20160220704-A1 | PYRIDAZINOINDOLE COMPOUNDS AND METHODS FOR PET IMAGING | VANDERBILT UNIVERSITY | 2016-08-04 | — | — | US | disclosed |
| US-8841320-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY | 2014-09-23 | — | — | US | disclosed |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | VANDERBILT UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130059343-A1 | NUCLEOTIDE DERIVATIVES | LI-COR, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-8372868-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2013-02-12 | — | — | US | disclosed |
| US-8367714-B2 | Cannabinoid receptor targeted agent | VANDERBILT UNIVERSITY (US) | 2013-02-05 | — | — | US | disclosed |
| US-8188116-B2 | Ligand/drug conjugates; near infrared radiation imaging; peripheral benzodiazepine receptor imaging; drug delivery; drug targets; cancer, metastasis | VANDERBILT UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100324130-A1 | DAA PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR CANCER IMAGING AND TREATMENT | US ARMY, SECRETARY OF THE ARMY | 2010-12-23 | — | — | US | disclosed |
| US-20100278739-A1 | TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING | VANDERBILT UNIVERSITY | 2010-11-04 | — | — | US | disclosed |
| US-7754884-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090105128-A1 | CANNABINOID RECEPTOR TARGETED AGENT | VANDERABILT UNIVERSITY | 2009-04-23 | — | — | US | disclosed |
| WO-2009029727-A1 | CANNABINOID RECEPTOR TARGETED AGENT | VANDERBILT UNIVERSITY (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-02-07 | — | — | US | disclosed |
| EP-1841466-A2 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | VANDERBILT UNIVERSITY (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006074129-A2 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | VANDERBILT UNIVERSITY (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060147379-A1 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY | 2006-07-06 | — | — | US | disclosed |
| EP-1019887-B1 | FLUORESCENT CYANINE DYES | LI COR INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6027709-A | BENZO(E)INDOLE-BASED DYES USEFUL AS REPORTER GROUPS FOR LABELING BIOMOECULES; SOLUBILITY RETAINED BY BIOMOLECULE; ATTACHMENT TO DNA, NUCLEOTIDES, PEPTIDES, HORMONES, ENZYMES ETC.; LASER ACTIVATION | LI-COR INC. (US) | 2000-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | TSPO, MKI67, CNR1 | MEN1 2657/4885KMT2A 3444/4885MCL1 879/4885 |
| US-20090105128-A1 | CANNABINOID RECEPTOR TARGETED AGENT | CNR1, CNR2, NPY1R | MEN1 1767/4885KMT2A 1556/4885MCL1 932/4885 |
| US-11027027-B2 | Pyridazinoindole compounds and methods for PET imaging | TSPO, SLC25A17, SLC19A2 | MEN1 482/4885KMT2A 4237/4885MCL1 4417/4885 |
| US-20160220704-A1 | PYRIDAZINOINDOLE COMPOUNDS AND METHODS FOR PET IMAGING | TSPO, SLC25A17, SLC19A2 | MEN1 482/4885KMT2A 4237/4885MCL1 4417/4885 |
| US-20100324130-A1 | DAA PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR CANCER IMAGING AND TREATMENT | GABRA6, GABRA1, GABRA4 | MEN1 1648/4885KMT2A 480/4885MCL1 581/4885 |
| US-20100278739-A1 | TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING | TSPO, MKI67, GABRA4 | MEN1 3250/4885KMT2A 2948/4885MCL1 653/4885 |
| US-20130059343-A1 | NUCLEOTIDE DERIVATIVES | NUDT1, DUT, NT5C3B | MEN1 2418/4885KMT2A 1725/4885MCL1 1316/4885 |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | TSPO, MKI67, GABRA4 | MEN1 3250/4885KMT2A 2948/4885MCL1 653/4885 |
| US-20060147379-A1 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | TSPO, MKI67, GABRA4 | MEN1 3250/4885KMT2A 2948/4885MCL1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.